Related Experiment Video
Updated: May 29, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Antifibrotic constituents from Garcinia mangostana
Young-Won Chin1, Eunjin Shin, Bang Yeon Hwang
1College of Pharmacy, Dongguk University-Seoul, Seoul 100-715, Korea.
Abstract:
From the CHCl3-soluble fraction of the fruits of Garcinia mangostana (Clusiaceae), six xanthone derivatives, alpha-mangostin (1), gamma-mangostin (2), gartanin (3), deoxygartanin (4), 1-isomangstanin (5) and garcinone E (6), were isolated. All these compounds significantly inhibited HSC-T6 viability as assessed by employing HSC-T6 hepatic stellate cells as an in vitro assay system. Among them, compounds 1 and 2, the most potent and major constituents of G. mangostana, inhibited HSC-T6 viability in dose- and time-dependent manners. In addition, compounds 1 and 2 significantly reduced collagen content, a pathological characteristic of liver fibrosis. Taken together, G. mangostana and its constituents might be beneficial for the treatment of liver fibrosis.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Action of β1 Blockers
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Types of β-Blockers